Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02076191 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | completed | Phase 1 / Phase 2 | 49 | John MascarenhasOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00416598 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 546 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)(EFFIKIR) | completed | Phase 2 | 152 | Innate PharmaINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01720264 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | completed | Phase 2 | 15 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT01824693 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | completed | Phase 2 | 30 | Children's Oncology GroupNETWORK | 4 | Dec 5, 2018 | clinicaltrials |
| NCT00075010 | Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00903760 | Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00065143 | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038597 | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01025154 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00425477 | Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 5, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01687400 | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 2 | 114 | Washington University School of MedicineOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02282215 | Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | completed | Phase 2 | 163 | Cellerant TherapeuticsINDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00001873 | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | completed | Phase 2 | 102 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00061581 | Experimental Bone Marrow Transplant Protocol | completed | Phase 2 | 14 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT00352001 | Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 37 | Mikkael Sekeres MDOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00451048 | Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 2 | Sep 4, 2018 | clinicaltrials |
| NCT00134017 | Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer | completed | Phase 2 | 142 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01253447 | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00422591 | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00542971 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | completed | Phase 1 / Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00068276 | Cholecalciferol in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00795002 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01452646 | Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia(AML1310) | completed | Phase 2 | 515 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00987480 | Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2019source: clinicaltrials